Pharmaco-economic evaluation of targeted hepatitis a vaccination for children of ethnic minorities in Amsterdam (The Netherlands)

Vaccine

Volumn 22, Issue 15-16, 2004, Pages 1862-1867

  Postma, M J ^a   Bos, J M ^a,b   Beutels, Ph ^c   Schilthuis, H ^d   Van Den Hoek, J A R ^d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d MUNICIPAL HEALTH SERVICE   (Netherlands)

Author keywords

Ethnic minorities; Hepatitis A vaccination; Pharmaco economic evaluation

Indexed keywords

HEPATITIS A VACCINE; UNCLASSIFIED DRUG; VAQTA JUNIOR;

ANALYTIC METHOD; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; ETHNOLOGY; HEALTH PROGRAM; HEPATITIS A; HUMAN; INFANT; MULTIVARIATE ANALYSIS; NETHERLANDS; PRIORITY JOURNAL; REIMBURSEMENT; SOCIAL ASPECT;

ADULT; CHILD; COST-BENEFIT ANALYSIS; DISEASE OUTBREAKS; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MINORITY GROUPS; NETHERLANDS; VACCINATION;

EID: 2342629348     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.012     Document Type: Article

References (34)

1. Kraaijeveld A.G. Hepatitis A vaccination for Turkish and Maroccan children (Hepatitis A-vaccinatie voor Turkse en Marokkaanse kinderen in Dutch). Infectieziekten Bull. 13:2002;6-7
2. Hoebe J.C.P.A. Hepatitis A epidemic in Heerlen late in 1996 the importance of immunisation of immigrant children (Hepatitis-A epidemie in Heerlen, eind 1996 het belang van immunisatie van migrantenkinderen in Dutch). Ned. Tijdschr. Geneeskd. 142:1998;521-525
3. Van Gorkum J., Leentvaar-Kuijpers A., Kool J.L., Coutinho R.A. Association between the yearly hepatitis A epidemic and travel behaviour of children of immigrants in the four major cities (Jaarlijkse epidemie van hepatitis A in verband gebracht met reisgedrag van kinderen van immigranten in de vier grote steden in Dutch). Ned. Tijdschr. Geneeskd. 142:1998;1919-1923
4. Schilthuis H. Hepatitis A in travellers often occurring but easily preventable (Hepatitis A bij Reizigers veel vóórkomend en toch goed te voorkómen in Dutch). Pharm. Weekblad. 135:2000;1147-1151
5. Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 10:S15-7.
6. Van Doorslaer E., Tormans G., van Damme P., Beutels Ph. Cost-effectiveness of alternative hepatitis A immunisation strategies. PharmacoEconomics. 8:1995;5-8
7. Beutels Ph, Edmunds WJ, Antoñanzas F, de Wit EA, Evans D, Feilden R, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. PharmacoEconomics 2002;20:1-7.
8. Dijkshoorn H., Schilthuis H.J., van den Hoek J.A.R., Verhoeff A.P. Travel advice on the prevention of infectious diseases insufficiently obtained by indigenous and non-native inhabitants of Amsterdam, the Netherlands (Onvoldoende bereik van reizigersadvisering over infectieziektepreventie onder autochtone an allochtone Amsterdammers in Dutch). Ned. Tijdschr. Geneeskd. 147:2003;658-662
9. Termorshuizen F., van de Laar M.J.W. Epidemiology of hepatitis A in the Netherlands, 1957-1998 (De epidemiologie van hepatitis A in Nederland, 1957-1998 in Dutch). Ned. Tijdschr. Geneeskd. 142:1998;2364-2368
10. College voor Zorgverzekeringen (CvZ). Guidelines for Pharmaco-economic Research (Richtlijnen voor farmaco-economisch onderzoek in Dutch). Amstelveen: CvZ; 1999.
11. Gold MR, Siegel JE, Russel LB, Weinstein (Eds.), Cost-effectiveness in health and medicine.
12. Municipal Health Service Amsterdam, personal communication.
13. Welling-Vis G.L.W., Ruijs W.L.M. Hepatis A in primary schools application of guidelines in practice (Hepatitis A op basisscholen hantering LCI-richtlijnen in de praktijk in Dutch). Infectieziekten Bull. 13:2002;131-136
14. College voor Zorgverzekeringen (CvZ). Farmacotherapeutic Compass 2001 (Farmacotherapeutisch Kompas 2001 in Dutch). Amstelveen: CvZ; 2000.
15. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Silrin R. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. New Engl. J. Med. 327:1992;453-457
16. Lee S.-D., Lo K.-J., Chan C.-Y., Yu M.Y., Wang Y.J., Safary A. Immunogenicity of inactivated hepatitis A vaccine in children. Gastroenterology. 104:1993;1129-1132
17. Demicheli V., Tiberti D. The effectiveness and safety of hepatitis A vaccine: a systematic review. Vaccine. 21:2003;2242-2245
18. André F.E., D'Hondt E.D., Delem A., Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine. 10:1992;S160-S168
19. Iwarson S., Lindh M., Widerstrom L. Excellent booster response 4-6 years after a single primary dose of inactivated hepatitis A vaccine. Scand. J. Infect. Dis. 34:2002;110-111
20. Landry P., Tremblay S., Darioli R., Genton B. Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine. 19:2000;399-402
21. GezondheidsRaad (GR). Universal vaccination against meningococcus C and pneumococci (Algemene vaccinatie tegen meningokokken C en pneumokokken in Dutch). Den Haag: GR; 2002.
22. Van Doorslaer E., Tormans G., van Damme P. Cost-effectiveness analysis of vaccination against hepatitis A in travellers. J. Med. Virol. 44:1994;463-469
23. Arnal J.M., Frisas O., Garuz R., Antonanzas F. Cost effectiveness of hepatitis A virus immunisation in Spain. PharmacoEconomics. 12:1997;361-373
24. Jacobs R.J., Margolis H.S., Coleman P.J. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch. Pediatr. Adolesc. Med. 154:2000;763-770
25. Postma M.J., van den Hoek J.A.R., Beck E.J., Heeg B., Jager J.C., Coutinho R.A. Pharmaco-economic evaluation of universal screening for HIV in pregnancy favourable cost-effectiveness for Amsterdam (Farmaco-economische evaluatie van universele HIV-screening in de zwangerschap een gunstige kosteneffectiviteit voor Amsterdam in Dutch). Ned. Tijdschr. Geneeskd. 144:2000;749-754
26. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Guidelines for costing methods and guidelineprices for economic evaluations in health care (Handleiding voor Kostenonderzoek methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg in Dutch). Amstelveen: College voor Zorgverzekeraars; 2000.
27. College voor Zorgverzekeraars (CvZ). Diagnostic compass 2001/2002 (Diagnostisch Kompas 2001/2002 in Dutch). Amstelveen: CvZ; 2001.
28. Michel B.C., Bonsel G.J., Stouthard M.E.A., McDonnel J., Habbema J.D.F. Cost-effectiveness analysis of renal transplant on the long term - the Groningen renal transplant program 1979-1991 (Kosten-effectiviteitsanalyse van levertransplantatie op lange termijn - het Groningse levertransplantatieprogramma 1979-1991 in Dutch). Ned. Tijdschr. Geneeskd. 137:1993;963-968
29. Jacobs R.J., Moleski R.J., Meyerhoff A.S. Valuation of symptomatic hepatitis A in adults. Estimates based on time trade-off and willingness-to-pay measurement. PharmacoEconomics. 20:2002;739-747
30. Postma M.J., Heijnen M.-L.A., Jager J.C. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in the Netherlands. PharmacoEconomics. 19:2001;215-222
31. Bonanni P., Colombai R., Franchi G., Lo Nostro A., Comodo N., Tiscione E. Experience of hepatitis A vaccination during an outbreak in a nursery school of Tuscany, Italy. Epidemiol. Infect. 121:1998;377-380
32. Irwin D.J., Millership S. Control of a community hepatitis A outbreak using hepatitis A vaccine. Commun. Dis. Public Health. 2:1999;184-187
33. Minister van Volksgezondheid, Welzijn en Sport. Regulations concerning hepatitis B vaccinations (Wijziging Regeling nadere regels zorgaanspraken AWBZ i.v.m. opname hepatitis B vaccinatie in het vaccinatieprogramma in Dutch). Staatscourant 2002;165:19.
34. van de Laar M.J.W., Wijgergangs L.M., Rijlaarsdam J., de Wit A. Vaccination against hepatitis A: an exploration of the costs (Vaccineren tegen hepatitis A: een verkenning van de kosten in Dutch). Infectieziekten Bull. 11:2000;262-266